Implementing Blue Light Flexible Cystoscopy in Bladder Cancer Surveillance

Published: 5 July 2019Medical Information
**A new publication reviews this shift in the treatment paradigm for bladder cancer patients, discussing clinical benefits and cost management of the procedure.** **Oslo, Norway, July 5, 2019**: Photocure ASA announced today that a review paper on Blue Light Cystoscopy (BLC™) with Hexvix®/Cysview® with focus on the use in the office setting with flexible cystoscopes was published in the peer reviewed European Medical Journal. With emerging data confirming similar clinical benefits for flexible BLC in the surveillance of non-muscle invasive bladder cancer (NMIBC) to its current use in rigid cystoscopy, the authors state that there is a clear opportunity for flexible BLC to assert a central role in the treatment paradigm. In a clinical study, around 1 in 5 confirmed malignancies were detected only by flexible BLC (p<0.0001)1 and the introduction of flexible BLC for routine surveillance post-TURBT is supported by consensus among bladder cancer specialists2. The need for long-term surveillance of patients with NMIBC following TURBT means that it is critical to evaluate the cost-effectiveness of any changes to the treatment and management of this common and expensive form of cancer, and the paper also discusses European studies based on health economic models that have demonstrated that the introduction of BLC results in reduced costs over time, in both the diagnostic and surveillance settings3,4. Read the publication here: 1 Daneshmand S et al. J Urol. 2018 2 Lotan Y et al. Nat Rev Urol. 2019 3 Witjes JA et al. Eur Urol. 2014 4 Dansk V et al. Future Oncol. 2016

News and events